The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Monalizumab plus durvalumab plus platinum-based chemotherapy for first-line treatment of extensive stage small-cell lung cancer: Early efficacy results from MOZART trial.
 
Hirva Mamdani
Honoraria - Regeneron (I)
Consulting or Advisory Role - ADC Therapeutics (I); ADC Therapeutics (I); AstraZeneca; AstraZeneca; Bristol-Myers Squibb/Medarex; Daiichi Sankyo/Astra Zeneca; Genmab (I)
Research Funding - AstraZeneca (Inst); Genentech (I); Genmab (I); Karyopharm Therapeutics (I)
Expert Testimony - AstraZeneca (I)
Travel, Accommodations, Expenses - AstraZeneca
 
Hyejeong Jang
No Relationships to Disclose
 
Seongho Kim
No Relationships to Disclose
 
Muhammad Furqan
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; BeiGene; BeiGene; Mirati Therapeutics
Speakers' Bureau - Binaytara Foundation - Education Academy
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Biothera (Inst); Bristol-Myers Squibb/Celgene (Inst); Celgene (Inst); Checkmate Pharmaceuticals (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Incyte (Inst); InhibRx (Inst); Jacobus Pharmaceutical Company (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Poseida Therapeutics (Inst); SOPHiA Genetics (Inst)
 
William Zeitler
No Relationships to Disclose
 
Misty Shields
Consulting or Advisory Role - AstraZeneca
 
Ryan Gentzler
Honoraria - Aptitude Health; Curio Science; IDEOlogy Health; OncLive
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Genentech; GlaxoSmithKline; Merus; Regeneron
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dizal Pharma (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Merck (Inst); nalo therapeutics (Inst); Pfizer (Inst); Prelude Therapeutics (Inst); Puma Biotechnology (Inst); Takeda (Inst); Tempus (Inst); Tempus (Inst)
Travel, Accommodations, Expenses - Tempus
 
Kristen Pizana
No Relationships to Disclose
 
Qura Abid
No Relationships to Disclose
 
Shadia Jalal
Research Funding - AstraZeneca/MedImmune